Logo
x

Search

Subscribe Now

 Lecanemab

BioArctic and Eisai Receives MAA from MHRA for Leqembi (lecanemab) to Treat Early Alzheimer’s Disease (AD) in Great Britain

BioArctic and Eisai Receives MAA from MHRA for Leqembi (lecanemab) to Treat Early Alzheimer’s Disease (AD) in Great Britain

  • August 22, 2024
Michael Irizarry, SVP, Clinical Research, Eisai Shared Insights on P-III Results from Clarity AD Study

Michael Irizarry, SVP, Clinical Research, Eisai Shared Insights on P-III Results from Clarity AD Study

  • July 5, 2023
BioArctic Partner Eisai Reports the MAA Submission to the MHRA for Lecanemab to Treat Early Alzheimer's Disease

BioArctic Partner Eisai Reports the MAA Submission to the MHRA for Lecanemab to Treat Early Alzheimer's Disease

  • May 22, 2023
Eisai and Biogen Report the Health Canada Acceptance of New Drug Submission for Leqembi (lecanemab) to Treat Early Alzheimer's Disease

Eisai and Biogen Report the Health Canada Acceptance of New Drug Submission for Leqembi (lecanemab) to Treat Early Alzheimer's Dis...

  • May 16, 2023
BioArctic & Eisai’s MAA for Lecanemab Receives Approval from the US FDA to Treat Early Alzheimer's Disease

BioArctic & Eisai’s MAA for Lecanemab Receives Approval from the US FDA to Treat Early Alzheimer's Disease

  • January 27, 2023
Eisai Reports MAA Submission of Leqembi (lecanemab) for Early Alzheimer's Disease in Japan

Eisai Reports MAA Submission of Leqembi (lecanemab) for Early Alzheimer's Disease in Japan

  • January 16, 2023
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.